Beacon Harbor Wealth Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.5M Buy
302,840
+194,544
+180% +$5.18M 1.78% 21
2025
Q4
$2.7M Sell
108,296
-136,827
-56% -$3.45M 0.6% 49
2025
Q3
$6.25M Buy
245,123
+54,263
+28% +$1.34M 1.46% 30
2025
Q2
$4.63M Sell
190,860
-70,393
-27% -$1.64M 1.15% 40
2025
Q1
$6.62M Buy
261,253
+166,788
+177% +$4.36M 1.54% 31
2024
Q4
$2.51M Sell
94,465
-141,745
-60% -$3.84M 0.58% 49
2024
Q3
$6.84M Buy
236,210
+3,169
+1% +$92.4K 1.63% 27
2024
Q2
$6.52M Buy
233,041
+3,754
+2% +$103K 1.7% 21
2024
Q1
$6.36M Buy
+229,287
New +$6.36M 1.68% 25

Other funds holding PFE

Beacon Harbor Wealth Advisors's PFE Position: Q1 2026 in Review

Beacon Harbor Wealth Advisors increased its Pfizer (PFE) stake by 180% in Q1 2026, buying an estimated $5.18M and bringing the position to 302,840 shares worth $8.5M. The position accounts for 1.78% of the portfolio, ranked #21.

Beacon Harbor Wealth Advisors first reported a position in PFE in Q1 2024 and has held it in 9 quarters since. 2,939 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Beacon Harbor Wealth Advisors held 302,840 shares of Pfizer worth $8.5M as of Q1 2026.
  • Beacon Harbor Wealth Advisors bought 194,544 Pfizer shares in Q1 2026, an estimated $5.18M.
  • Pfizer made up 1.78% of Beacon Harbor Wealth Advisors's portfolio in Q1 2026, its #21 holding.
  • Beacon Harbor Wealth Advisors first reported a position in Pfizer in Q1 2024 and has held it in 9 quarters since.
  • 2,939 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Beacon Harbor Wealth Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.